Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 7, 2004. The report serves as a notification of specific corporate governance events and corrections regarding share transactions rather than a comprehensive financial results announcement.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific director's share transaction:
- Share Price: £12.00 per share (used for dividend reinvestment).
- Transaction Volume: 126 Ordinary Shares.
Material Changes and Corrections
The filing addresses two primary material items:
- Correction of Prior Announcement: The Company retracted Announcement 1437D issued on September 20, 2004. The GlaxoSmithKline Employee Trust incorrectly notified the Company of a transfer of 34,172 shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company confirmed that no shares were actually transferred.
- Director's Interest Change: Director Mr. J D Coombe increased his interest in the Company by 126 Ordinary Shares on October 7, 2004, through the reinvestment of dividends paid on September 30, 2004.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is strictly administrative in nature.
Key Facts for Investor Verification
- Verify that Announcement 1437D (dated September 20, 2004) regarding the transfer of 34,172 shares is officially retracted and should be disregarded.
- Confirm the updated shareholding interest of Director Mr. J D Coombe following the October 7, 2004 dividend reinvestment.
- Note that this filing does not contain quarterly or annual financial performance data.